» Articles » PMID: 1962617

Opportunistic Infections of the Esophagus Not Responding to Oral Systemic Antifungals in Patients with AIDS: Their Frequency and Treatment

Overview
Specialty Gastroenterology
Date 1991 Dec 1
PMID 1962617
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

To determine the spectrum of esophageal disease responsible for dysphagia/odynophagia in AIDS patients not responding to current oral antifungals, we studied 49 consecutive patients whose esophageal symptoms failed to improve after a minimum of 3 wk of therapy with oral ketoconazole or fluconazole. An esophageal candidiasis resistant to oral antifungals was the most frequent disease found (22 single infections and four mixed with viruses). Viral esophagitis was identified in 13 cases (eight herpes simplex virus and five cytomegalovirus), and an esophagitis of unknown origin was documented in two patients. Other causes of symptoms included peptic esophagitis (four cases), esophageal stenosis (two cases), and Kaposi's sarcoma of the esophagus (one patient). Most patients with esophageal opportunistic infection experienced prompt relief of symptoms and complete endoscopic resolution on the specific antifungal (amphotericin B or fluconazole iv) or antiviral (acyclovir or gancyclovir iv) therapy, with the exception of those with concomitant fungal and viral infection who responded poorly to treatment. We conclude that most AIDS patients with dysphagia/odynophagia who do not respond to oral antifungals have an opportunistic infection of the esophagus. Nevertheless, specific antifungal or antiviral therapy is worthwhile, because it will eradicate, at least temporarily, the causative pathogens in most such patients.

Citing Articles

Diagnostic value of antigenemia assay for cytomegalovirus gastrointestinal disease in immunocompromised patients.

Nagata N, Kobayakawa M, Shimbo T, Hoshimoto K, Yada T, Gotoda T World J Gastroenterol. 2011; 17(9):1185-91.

PMID: 21448424 PMC: 3063912. DOI: 10.3748/wjg.v17.i9.1185.


Natural history of HIV-associated esophageal disease in the era of protease inhibitor therapy.

Bini E, Micale P, Weinshel E Dig Dis Sci. 2000; 45(7):1301-7.

PMID: 10961707 DOI: 10.1023/a:1005591617142.


Evaluating diagnosis and treatment of oral and esophageal candidiasis in Ugandan AIDS patients.

Ravera M, Reggiori A, Agliata A, ROCCO R Emerg Infect Dis. 1999; 5(2):274-7.

PMID: 10221882 PMC: 2640695. DOI: 10.3201/eid0502.990214.


Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients.

Quereda C, Polanco A, Giner C, Sanchez-Sousa A, Pereira E, Navas E Eur J Clin Microbiol Infect Dis. 1996; 15(1):30-7.

PMID: 8641300 DOI: 10.1007/BF01586182.


In vitro susceptibility and sterol biosynthesis of Candida albicans strains after long-term treatment with azoles in HIV-infected patients.

Hundt W, Hofmann H Infection. 1994; 22(2):124-31.

PMID: 8070926 DOI: 10.1007/BF01739023.